Synergistic Anticancer Effect of a Combination of Paclitaxel and 5-Demethylnobiletin Against Lung Cancer Cell Line In Vitro and In Vivo
- 116 Downloads
Lung cancer remains a highly prevalent disease and a leading cause of cancer-related deaths worldwide. Currently, exploring antitumor drugs derived from herbs used in traditional Chinese medicine is increasingly becoming an attractive area of research. Paclitaxel (PTX), a highly effective chemotherapeutic drug, is widely used for treating different cancers; however, the clinical use of PTX is dose limited because of its adverse side effects. Chemotherapeutic agents are being developed to enhance the anticancer activity of PTX, particularly for use in combination therapy. 5-Demethylnobiletin (5-DMN), a natural, active compound isolated from orange peel, has been reported to induce apoptosis in several cancer cell lines. In this study, we tested the synergistic anticancer antiproliferative effects of combinations of PTX and 5-DMN on CL1–5 lung cancer cells through the MTT and propidium iodide assays. After low-dose combination treatments (PTX and 5-DMN), a reduction in cell viability and a concomitant increase in apoptosis were observed in the CL1–5 cells. We propose that 5-DMN cooperates with PTX to induce apoptosis via the caspase pathway (by modulating caspase-3, caspase-8, and caspase-9 activities). Furthermore, we observed that the combination treatment significantly suppressed tumor growth in the nude mouse xenograft model. The results suggest that the synergistic effects of PTX and 5-DMN in lung cancer cells deserve particular attention and indicate the possibility of developing additional new strategies for treating lung cancer.
KeywordsPaclitaxel 5-Demethylnobiletin Non-small cell lung cancer Apoptosis Synergistic effect
This study was supported by grants (106-CCH-IRP-072) from Changhua Christian Hospital, Taiwan.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., Cortinovis, D. L., Leach, J., Polikoff, J., Barrios, C., Kabbinavar, F., Frontera, O. A., De Marinis, F., Turna, H., Lee, J. S., Ballinger, M., Kowanetz, M., He, P., Chen, D. S., Sandler, A., Gandara, D. R., & OAK Study Group. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 389(10066), 255–265.CrossRefGoogle Scholar
- 7.Goteti, K., Garner, C., Utley, L., Dai, J., Ashwell, S., Moustakas, D. T., Gönen, M., Schwartz, G. K., Kern, S. E., Zabludoff, S., & Brassil, P. J. (2010). Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer Chemotherapy and Pharmacology, 66(2), 245–254.CrossRefGoogle Scholar
- 8.Nikolic, V. D., Savic, I. M., Savic, I. M., Nikolic, L. B., Stankovic, M. Z., & Marinkovic, V. D. (2011). Paclitaxel as an anticancer agent: isolation, activity, synthesis and stability. Central European Journal of Medicine, 6, 527–536.Google Scholar
- 9.Asik, A., Kayabasi, C., Ozmen Yelken, B., Yılmaz Susluer, S., Dogan Sigva, Z. O., Balcı Okcanoglu, T., Saydam, G., Biray Avci, C., & Gunduz, C. (2018). Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line. Gene, S0378–1119, 30024–30026.Google Scholar
- 10.Li, S., Lambros, T., Wang, Z., Goodnow, R., & Ho, C. T. (2007). Efficient and scalable method in isolation of polymethoxyflavones from orange peel extract by supercritical fluid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 846(1-2), 291–297.CrossRefGoogle Scholar
- 12.Chen, Y. K., Wang, H. C., Ho, C. T., Chen, H. Y., Li, S., Chan, H. L., Chung, T. W., Tan, K. T., Li, Y. R., & Lin, C. C. (2015). 5-demethylnobiletin promotes the formation of polymerized tubulin, leads to G2/M phase arrest and induces autophagy via JNK activation in human lung cancer cells. The Journal of Nutritional Biochemistry, 26(5), 484–504.CrossRefGoogle Scholar
- 19.Chou, T. C., & Martin, N. (2005). A computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values. ComboSyn; Paramus, NJ. CompuSyn for drug combinations: PC software and user’s guide.Google Scholar
- 20.Chou, T. C. (1991). The median-effect principle and combination index for quantitation of synergism and antagonism. In T. C. Chou & D. C. Rideout (Eds.), Synergism and antagonism in chemotherapy (pp. 61–102). San Diego: Academic Press.Google Scholar
- 21.Chou, T. C., Motzer, R. J., Tong, Y., & Bosl, G. J. (1994). Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. Journal of the National Cancer Institute, 86(20), 1517–1524.CrossRefGoogle Scholar
- 23.Hanna, R. K., Zhou, C., Malloy, K. M., Sun, L., Zhong, Y., Gehrig, P. A., & Bae-Jump, V. L. (2012). Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecologic Oncology, 125(2), 458–469.CrossRefGoogle Scholar
- 26.Alexandre, J., Batteux, F., Nicco, C., Chéreau, C., Laurent, A., Guillevin, L., Weill, B., & Goldwasser, F. (2006). Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. International Journal of Cancer, 119(1), 41–48.CrossRefGoogle Scholar